Bristol-Myers Squibb

Be Biopharma, Inc. is focused on developing innovative therapeutics derived from engineered B-cells to address various diseases, including cancer, autoimmune disorders, and infectious diseases. Founded in 2020 and based in Cambridge, Massachusetts, the company aims to overcome significant challenges associated with traditional cell and gene therapies, such as the limitations of dosing, unpredictable reactions in patients, and the necessity of pre-treatment chemotherapy. By leveraging precision genome editing, Be Biopharma creates durable and effective cell therapies that can be administered without toxic conditioning, thereby improving treatment options for conditions like Hemophilia B and enhancing overall patient outcomes.

Light Horse Therapeutics is a biotechnology company specializing in the application of gene editing to small-molecule drug discovery. It develops innovative methods to target the root causes of severe and life-threatening diseases, with an initial focus on challenging oncology targets. The company's advanced platform identifies critical functional domains within disease-related proteins, enabling the development of novel therapies.

Be Biopharma, Inc. is focused on developing innovative therapeutics derived from engineered B-cells to address various diseases, including cancer, autoimmune disorders, and infectious diseases. Founded in 2020 and based in Cambridge, Massachusetts, the company aims to overcome significant challenges associated with traditional cell and gene therapies, such as the limitations of dosing, unpredictable reactions in patients, and the necessity of pre-treatment chemotherapy. By leveraging precision genome editing, Be Biopharma creates durable and effective cell therapies that can be administered without toxic conditioning, thereby improving treatment options for conditions like Hemophilia B and enhancing overall patient outcomes.

Aktis Oncology is a biotechnology company focused on developing targeted radiopharmaceuticals for the treatment of various solid tumor cancers. The company has created proprietary platforms that generate tumor-targeting agents optimized for alpha radiotherapy. These agents are engineered to achieve high penetration into tumors and prolonged residence time, allowing for effective tumor elimination while reducing side effects associated with treatment. Additionally, Aktis Oncology's innovative approach enables clinicians to visualize and confirm target engagement before administering therapeutic radioisotopes, enhancing the precision of cancer treatment.

Abata Therapeutics is dedicated to developing innovative cell therapies aimed at treating autoimmune and inflammatory diseases, particularly progressive multiple sclerosis and type 1 diabetes. The company focuses on harnessing regulatory T cells (Tregs) to restore balance in the immune system, engineering these cells to specifically target disease-related antigens for precise treatment. This approach allows for effective disease management without the need for systemic immune suppression, enabling patients to maintain stable and active tissue residency. Founded by experts in immunology and cell therapy, Abata has garnered substantial investment from venture capital and biopharmaceutical firms, with the mission of translating advanced scientific research into meaningful therapies that enhance the quality of life for individuals affected by chronic autoimmune conditions.

Roswell Park Cancer Institute (RPCI), established in 1898 by Dr. Roswell Park, is recognized as America's first cancer center. It pioneered a multidisciplinary approach to cancer treatment, emphasizing collaboration between scientists and clinicians, which has become the benchmark for modern comprehensive cancer centers. RPCI is one of the few facilities in upstate New York designated as a "comprehensive cancer center" by the National Cancer Institute and is a member of the National Comprehensive Cancer Network (NCCN). Faculty at RPCI are actively involved in developing Clinical Practice Guidelines in Oncology™, which are the internationally recognized standards for oncology clinical policy and are continually updated to reflect the latest advancements in cancer treatment.

Envisagenics, Inc. is a biotechnology company founded in 2013 and headquartered in Huntington, New York. It specializes in the development of a predictive analytics platform aimed at accelerating the discovery of RNA therapeutics. The company leverages advanced artificial intelligence and machine learning algorithms to analyze transcriptomic data, helping researchers identify and validate potential drug targets. Envisagenics' flagship technology, SpliceCore, is a cloud-based platform that utilizes RNA splicing analytics to predict drug targets and biomarkers, addressing the complexities of biomedical data. Given that over 30 million people in the U.S. suffer from genetic diseases or cancers related to RNA splicing errors, the company's mission is to streamline the development of innovative therapeutic solutions. By providing an in-silico RNA therapeutics discovery platform, Envisagenics enhances the efficiency of drug development processes, reducing time, cost, and risk associated with bringing new therapies to market through partnerships with biopharmaceutical companies.

Asher Biotherapeutics, Inc. is a biotechnology company based in South San Francisco, California, founded in 2019. The company specializes in the development of immunotherapy drugs aimed at effectively treating cancer. Its innovative therapies are designed to enhance the immune system's ability to target and eliminate cancer cells while minimizing side effects. This focus allows healthcare providers to deliver effective treatments to patients in a shorter timeframe, aiming to improve overall outcomes in cancer care.

RayzeBio, Inc. is a biotechnology company based in San Diego, California, founded in 2020. It specializes in developing tumor-targeted small molecule medicines that utilize the therapeutic potential of radioisotopes, particularly Actinium-225, an alpha-emitting radioisotope aimed at treating solid tumors. RayzeBio is focused on enhancing cancer treatment outcomes by creating a robust pipeline of radiopharmaceutical candidates targeting validated oncology drug targets. The company's portfolio includes a range of drug candidates at various stages of development, from discovery to late-stage clinical programs, addressing significant market opportunities in the field of cancer therapeutics.

Cour Pharmaceuticals Development Co Inc, founded in 2012 and based in Elmhurst, Illinois, operates in the pharmaceutical sector with a focus on developing an immune-modifying platform. This platform aims to achieve antigen-specific tolerance for immune-mediated diseases and provides non-biological therapeutics for conditions such as acute inflammation, autoimmunity, and allergies. The company is engaged in the pharmaceutical development of products related to immunology, pathology, and cardiovascular health, enabling the treatment of various conditions, including encephalitis syndromes, autoimmune disorders, infections, and heart attacks.

GlycoEra is a biotechnology research company focused on developing innovative therapeutics to address significant unmet medical needs in areas such as inflammatory diseases, autoimmune disorders, and immune-oncology. The company utilizes a proprietary platform to create first-in-class biologics that feature customized and highly homogeneous human glycans assembled onto glycoproteins in a site-specific manner. This approach enables healthcare companies to gain insights into the role of glycans in human health and disease, ultimately advancing the development of novel treatments.

Karuna Therapeutics is a clinical-stage biopharmaceutical company based in Boston, Massachusetts, dedicated to developing innovative therapies for neuropsychiatric disorders and pain. Its lead product candidate, KarXT, is an oral modulator that has completed a Phase II clinical trial for treating acute psychosis in schizophrenia patients and is undergoing a Phase Ib clinical trial for various central nervous system disorders, including cognitive and negative symptoms of schizophrenia, Alzheimer’s, and dementia-related psychosis. The company is also developing additional muscarinic-targeted drug candidates to address unmet medical needs in these areas. Founded in 2009, Karuna Therapeutics has established partnerships with organizations such as Eli Lilly and Company and PureTech Health LLC, focusing on advancing its drug discovery efforts through collaborations with Charles River Laboratories and PsychoGenics Inc.

AstronauTx is a biotechnology company focused on developing treatments for Alzheimer's disease and other neurodegenerative conditions. The company aims to restore the normal functioning of astrocytes, which are crucial cells in the brain that support neuronal activity, metabolism, and the integrity of the blood-brain barrier. In conditions such as dementia, astrocytes can become dysfunctional, leading to neurotoxicity and exacerbating disease progression. By targeting astrocyte homeostasis, AstronauTx seeks to enable healthcare professionals to effectively address the underlying mechanisms of neurotoxicity associated with these diseases, ultimately improving treatment options for patients suffering from dementia and related disorders.

immatics is a biopharmaceutical company focused on the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors. The company's customized Adoptive Cell Therapies (ACTengine) and antibody-like TCR Bispecifics are the two main product classes in the pipeline (TCER). With a focus on particularly difficult-to-treat solid malignancies, each therapy modality has unique characteristics to create the desired therapeutic impact for patients at various disease stages and with various types of tumors. immatics biotechnologies was established in 2000 by Hans Rammensee, Harpreet Singh, and Steffen Walter in Tübingen, Baden-Wurttemberg.

TORL BioTherapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative antibody-based medicines aimed at improving outcomes for cancer patients. The company specializes in creating antibody-drug conjugates (ADCs) and monoclonal antibodies (mAbs) to address oncologic diseases that exhibit significant unmet medical needs. TORL BioTherapeutics employs a strategic approach that includes target identification and early discovery work, allowing them to license promising drug programs and develop proprietary therapies with optimized characteristics. Through this pipeline, TORL BioTherapeutics is positioned to advance novel treatments that could significantly enhance patient care in oncology.

Penn Medicine Princeton Cancer Center provides access to the specialist clinical services, rehabilitative care, and support required during cancer treatment and recovery from cancer.

iVexSol Inc. specializes in developing lentiviral vector manufacturing technology aimed at addressing the shortage of lentiviral vectors (LVVs), which are essential for gene therapy programs. Established in 2018 and based in Worcester, Massachusetts, the company offers a platform that produces a consistent supply of LVVs, critical for the manufacture of cell and gene therapies (CGTs). By utilizing banks of vector-producing cells, iVexSol's technology significantly increases production capacity while minimizing complexity and development time. This innovative approach not only reduces costs but also accelerates the clinical development timelines, ultimately enhancing patient access to life-saving treatments. The company’s solutions are designed to support researchers and manufacturers in the CGT field, facilitating the treatment of serious conditions such as late-stage cancers and genetic disorders.

Cajal Neuroscience is a biotechnology company focused on developing innovative therapies for neurodegenerative diseases. By integrating human genetics, functional genomics, and advanced microscopy, the company aims to identify novel therapeutic targets. Cajal utilizes a range of cutting-edge technologies, including high-throughput functional genomics and multi-omics approaches, to screen for targets that significantly influence the progression of neurodegenerative diseases. This comprehensive methodology supports the development of precision medicine, ultimately aiding healthcare professionals in treating patients affected by these conditions.

Kura Oncology is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing targeted therapies for cancer treatment. The company’s primary product candidate, Tipifarnib, is an orally available farnesyl transferase inhibitor currently undergoing Phase II clinical trials for solid tumors, peripheral T-cell lymphomas, and various hematologic malignancies. In addition to Tipifarnib, Kura is advancing other small molecule candidates, including KO-947, which targets dysregulated extracellular signal-related kinases, and KO-539, aimed at inhibiting the menin-mixed lineage leukemia protein interaction. Kura Oncology emphasizes precision medicine, leveraging insights from cancer genomics to create targeted treatments for patients with specific genetic profiles, addressing significant unmet medical needs across various cancer types, including lung, colorectal, thyroid, pancreatic cancers, and blood cancers such as lymphoma and leukemia. The company was founded in 2014 and operates primarily within the United States.

SyntheX, Inc. is a biotechnology company based in San Francisco, California, that specializes in drug discovery focused on therapeutic applications, particularly in oncology. Founded in 2016, SyntheX employs a proprietary screening platform that utilizes synthetic biology to expand the druggable proteome. This platform enables the identification of protein interaction modulators through empirical intracellular selection, allowing for the discovery of compounds that can disrupt specific protein-protein interactions or facilitate functional protein degradation. The company's development portfolio includes stabilized peptide therapeutics, such as STX101 and STX105, aimed at treating cancers that utilize homologous recombination for chemotherapy evasion. SyntheX's approach integrates advanced technologies and engineered circuits to create a robust internal pipeline targeting genetically validated therapeutic mechanisms, while also engaging in external discovery collaborations.

Autobahn Therapeutics, Inc. is a biotechnology company based in San Diego, California, focused on developing small molecule therapies for central nervous system (CNS) disorders. Since its incorporation in 2017, Autobahn has aimed to address significant unmet needs in neuropsychiatry and neuroimmunology through its innovative brain-targeting chemistry platform. The company's leading candidate, ABX-002, is a thyroid hormone receptor beta agonist being investigated as a potential treatment for multiple sclerosis and adrenomyeloneuropathy, as well as an adjunctive therapy for major depressive disorder and bipolar disorder depression. Autobahn Therapeutics emphasizes precision tuning of CNS exposure, targeting validated clinical and biological markers to enhance therapeutic opportunities and patient outcomes.

Turning Point Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative small molecule targeted therapies for oncology. The company designs a range of tyrosine kinase inhibitors (TKIs) aimed at addressing genetic drivers of cancer in both TKI-naïve and TKI-pretreated patients. Its lead drug candidate, repotrectinib, is currently under evaluation in the ongoing Phase I/II TRIDENT-1 trial, targeting patients with ROS1+ advanced non-small-cell lung cancer and those with ROS1+, NTRK+, or ALK+ advanced solid tumors. Additionally, Turning Point's pipeline includes other multi-targeted drug candidates, such as TPX-0046, a RET/SRC inhibitor; TPX-0022, a MET/CSF1R/SRC inhibitor; and TPX-0131, which is an ALK inhibitor in preclinical development. Founded in 2013 and headquartered in San Diego, California, the company aims to advance precision medicine in oncology by addressing unmet medical needs.

Sapience Therapeutics, Inc. is a biotechnology company dedicated to the discovery and development of peptide-based therapeutics aimed at treating high mortality cancers. Founded in 2015 and headquartered in Harrison, New York, the company focuses on advancing innovative treatments for major unmet medical needs, particularly glioblastoma multiforme (GBM), the most aggressive form of brain cancer. Its lead product, ST101, functions as an inhibitor of C/EBPß, a transcription factor that is often overexpressed in various cancers and plays a role in cellular differentiation, tumor survival, and proliferation. ST101 targets and reduces the expression of several genes and proteins linked to cancer cell survival and growth, inducing selective cytotoxicity across multiple tumor types, including breast cancer, melanoma, prostate cancer, GBM, lung cancer, and acute myeloid leukemia. Through its research, Sapience Therapeutics aims to translate scientific advancements into effective therapies that address oncogenic and immune dysregulation in cancer.

Nuvig Therapeutics is focused on developing innovative therapies aimed at restoring immune homeostasis and rebalancing immune function, particularly following inflammation. The company is building a pipeline of novel immune therapeutics specifically designed for chronic inflammatory and autoimmune diseases. By leveraging natural mechanisms to modulate immune responses, Nuvig seeks to enhance treatment options available to healthcare providers and improve patient outcomes.

Be Biopharma, Inc. is focused on developing innovative therapeutics derived from engineered B-cells to address various diseases, including cancer, autoimmune disorders, and infectious diseases. Founded in 2020 and based in Cambridge, Massachusetts, the company aims to overcome significant challenges associated with traditional cell and gene therapies, such as the limitations of dosing, unpredictable reactions in patients, and the necessity of pre-treatment chemotherapy. By leveraging precision genome editing, Be Biopharma creates durable and effective cell therapies that can be administered without toxic conditioning, thereby improving treatment options for conditions like Hemophilia B and enhancing overall patient outcomes.

Century Therapeutics, Inc. is a biotechnology company focused on developing innovative cell therapies derived from induced pluripotent stem cells (iPSCs) to treat hematologic and solid malignancies. Founded in 2018 and headquartered in Philadelphia, Pennsylvania, the company utilizes a specialized platform that integrates gene editing and protein engineering to create allogeneic therapies. This platform allows for the generation of master cell banks of modified immune effector cells, specifically engineered to optimize performance and reduce the risk of rejection by the host immune system. By employing advanced technologies such as CRISPR-mediated gene editing and proprietary chimeric antigen receptors, Century Therapeutics aims to address significant unmet medical needs in cancer and other diseases.

Compugen Ltd. is a clinical-stage therapeutic discovery and development company headquartered in Holon, Israel. It specializes in the research, development, and commercialization of novel therapeutic candidates primarily in the field of cancer immunotherapy. The company's immuno-oncology pipeline includes several clinical-stage programs, such as COM701, an anti-PVRIG antibody, and COM902, which targets TIGIT, both designed for the treatment of solid tumors. Compugen employs advanced computational methods for drug discovery, utilizing in silico techniques to predict and select promising drug targets, followed by rigorous experimental validation. The company collaborates with major pharmaceutical partners, including Bayer Pharma AG and Bristol-Myers Squibb, to enhance its research and development efforts. Compugen's focus on innovative therapeutic solutions aims to address significant unmet medical needs in oncology, leveraging its unique predictive capabilities and a robust pipeline of early-stage programs targeting immune resistance mechanisms.

Nitrase Therapeutics is a biopharmaceutical platform company focused on developing therapies targeting a newly identified class of enzymes known as Nitrases. Initially concentrating on Parkinson’s disease, the company aims to create drugs that may slow or halt the progression of this and other related neurodegenerative conditions. By leveraging its expertise in nitration, Nitrase Therapeutics seeks to explore the therapeutic potential of biochemical modifications of proteins, particularly through the identification of nitro-substrates and their involvement in various diseases. This approach positions the company to potentially expand its platform to address a broader range of medical conditions in the future.

IMIDomics is a company focused on addressing Immune-Mediated Inflammatory Diseases (IMIDs) through innovative approaches in biomarker discovery and treatment monitoring. By leveraging the world's largest IMID biobank, along with extensive clinical expertise and advanced genomic analysis, IMIDomics aims to enhance patient care. The company has developed an analytical software platform that extracts valuable insights from vast amounts of molecular and clinical data, making it accessible for healthcare professionals without requiring specialized bioinformatics knowledge. This facilitates optimized treatment strategies for IMID patients. Headquartered at Vall d'Hebron Hospital in Barcelona, Spain, and with a presence at the HudsonAlpha Institute in Huntsville, Alabama, IMIDomics is positioned at the forefront of research and application in the field of immune-mediated diseases.

Allyx Therapeutics, founded in 2018 and based in Durham, Connecticut, is a clinical-stage biotechnology company focused on developing disease-modifying treatments for Alzheimer's Disease. The company’s primary product is an orally bioavailable small molecule that functions as a silent allosteric modulator of mGluR5. This innovative drug aims to reverse neurodegeneration and offers a potential approach to preserve cognitive function in patients with Alzheimer's. By targeting the underlying mechanisms of the disease, Allyx Therapeutics strives to provide effective therapeutic solutions for those affected by neurodegenerative disorders.

Aktis Oncology is a biotechnology company focused on developing targeted radiopharmaceuticals for the treatment of various solid tumor cancers. The company has created proprietary platforms that generate tumor-targeting agents optimized for alpha radiotherapy. These agents are engineered to achieve high penetration into tumors and prolonged residence time, allowing for effective tumor elimination while reducing side effects associated with treatment. Additionally, Aktis Oncology's innovative approach enables clinicians to visualize and confirm target engagement before administering therapeutic radioisotopes, enhancing the precision of cancer treatment.

Exscientia is a biotechnology company that leverages artificial intelligence and machine learning to enhance the discovery and design of novel therapeutic compounds. By integrating human expertise with advanced computational techniques, Exscientia accelerates the development of small-molecule drug candidates, aiming to produce safe and effective treatments for clinical testing. The company's innovative approach seeks to revolutionize the pharmaceutical industry by improving the precision and efficiency of drug discovery, ultimately enhancing patient outcomes.

Presage Biosciences, Inc. is an oncology company based in Seattle, Washington, founded in 2008. The company has developed an innovative platform known as the CIVO arrayed microinjection system, which allows for the simultaneous evaluation of multiple drugs or drug combinations directly within a patient's tumor. This technology assesses efficacy, resistance, and drug synergies in the tumor's native microenvironment, overcoming the limitations of traditional systemic drug administration. By employing its clinical surrogate approach, Presage enables drug developers to identify ineffective compounds early in the process, thereby streamlining drug development. Additionally, the technology facilitates the identification of effective drug combinations and targets using RNA interference, providing a more accurate measurement of treatment efficacy tailored to individual patient responses.

Ikena Oncology, Inc. is a biotechnology company focused on discovering and developing biomarker-driven therapies for cancer treatment. It specializes in precision oncology by targeting pathways essential for cancer growth and therapeutic resistance, particularly within the Hippo and RAS signaling networks. The company's portfolio includes several preclinical and discovery-stage programs, such as IK-007, an EP4 receptor antagonist; IK-175, an AHR antagonist; and IK-412, a kynurenine-degrading enzyme. Additionally, Ikena is developing IK-930, an oral small-molecule inhibitor of the TEAD transcription factor involved in the Hippo pathway. Ikena Oncology, originally founded as Kyn Therapeutics in 2016, rebranded in December 2019 and is headquartered in Boston, Massachusetts. The company aims to address significant medical needs in oncology through innovative drug development.

MyoKardia, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing targeted therapies for rare cardiovascular diseases. Founded in 2012 and headquartered in Brisbane, California, the company primarily addresses heritable cardiomyopathies and genetically-driven heart failure caused by biomechanical defects in cardiac muscle contraction. Its lead product candidate, Mavacamten, is an orally administered allosteric modulator of cardiac myosin currently in Phase III trials for hypertrophic cardiomyopathy (HCM). Additionally, MyoKardia is developing Danicamtiv, an orally administered small molecule that has completed Phase I and IIa trials for dilated cardiomyopathy. The company also has several preclinical programs, including MYK-224 for HCM, ACT-1 for diastolic dysfunction, and LUS-1 for diastolic dysfunction. As of late 2020, MyoKardia operates as a subsidiary of Bristol-Myers Squibb Company.

Forbius, also known as Formation Biologics, is a clinical-stage company focused on designing and developing biotherapeutics for cancer and fibrotic diseases. Founded in 2011 as a management-led spin-out from YM BioSciences, Forbius specializes in creating agents that target the transforming growth factor-beta (TGF-beta) and epidermal growth factor receptor (EGFR) pathways. The company aims to provide highly active inhibitors of these validated pathways, utilizing its expertise in biology and protein engineering technologies to develop novel therapeutic options. Through their innovative approach, Forbius seeks to significantly improve patient outcomes and transform the treatment landscape for challenging diseases.

Autobahn Therapeutics, Inc. is a biotechnology company based in San Diego, California, focused on developing small molecule therapies for central nervous system (CNS) disorders. Since its incorporation in 2017, Autobahn has aimed to address significant unmet needs in neuropsychiatry and neuroimmunology through its innovative brain-targeting chemistry platform. The company's leading candidate, ABX-002, is a thyroid hormone receptor beta agonist being investigated as a potential treatment for multiple sclerosis and adrenomyeloneuropathy, as well as an adjunctive therapy for major depressive disorder and bipolar disorder depression. Autobahn Therapeutics emphasizes precision tuning of CNS exposure, targeting validated clinical and biological markers to enhance therapeutic opportunities and patient outcomes.

Exscientia is a biotechnology company that leverages artificial intelligence and machine learning to enhance the discovery and design of novel therapeutic compounds. By integrating human expertise with advanced computational techniques, Exscientia accelerates the development of small-molecule drug candidates, aiming to produce safe and effective treatments for clinical testing. The company's innovative approach seeks to revolutionize the pharmaceutical industry by improving the precision and efficiency of drug discovery, ultimately enhancing patient outcomes.

Silverback Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Seattle, Washington, that specializes in developing tissue-targeted therapeutics aimed at treating cancer, chronic viral infections, and other serious diseases. The company’s lead product candidate, SBT6050, is currently undergoing a Phase I/Ib clinical trial; it is a TLR8 agonist conjugated to a HER2-directed monoclonal antibody, targeting tumors such as breast, gastric, and non-small cell lung cancers. Additionally, Silverback is advancing SBT6290, which is in preclinical development and targets Nectin4, found in bladder, triple-negative breast, head and neck, and non-small cell lung cancers. The company is also developing SBT8230, aimed at treating chronic hepatitis B virus infection, and exploring other agents that utilize its proprietary technology to modulate pathways in oncology and fibrosis indications. Silverback's innovative ImmunoTAC platform enables the design of therapies that are systemically delivered but act specifically at disease sites, unlocking previously inaccessible pathways for treatment.

Celgene Corporation is a global biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for cancer and immune-inflammatory diseases. The company aims to provide treatment options for patients with limited alternatives, conducting numerous clinical trials at major medical centers for its investigational compounds. Celgene's research primarily targets incurable hematological cancers, such as multiple myeloma, chronic lymphocytic leukemia, and non-Hodgkin’s lymphoma, as well as solid tumors like pancreatic cancer and melanoma. Additionally, the company is developing therapies for serious inflammatory conditions, including psoriasis and psoriatic arthritis. With a commitment to improving patient outcomes, Celgene continues to advance its pipeline of biopharmaceutical drugs.

Vedanta Biosciences, Inc. is a clinical-stage microbiome company based in Cambridge, Massachusetts, focused on developing therapies for immune-mediated and infectious diseases using human microbiome-derived bacteria. Established in 2010, the company utilizes microbial ecology and mucosal immunology to create innovative immunotherapies. Its platform includes a comprehensive library of bacteria sourced from the human microbiome, proprietary assays for selecting effective bacterial strains, and extensive datasets from human interventional studies. Vedanta also possesses cGMP-compliant manufacturing capabilities, allowing for the production of defined bacterial consortia in powder form. This enables the development of oral therapies aimed at treating autoimmune and inflammatory diseases, providing physicians with effective access to live bacterial drugs. Vedanta operates as a subsidiary of Pure Tech Health plc.

Celgene Corporation is a global biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for cancer and immune-inflammatory diseases. The company aims to provide treatment options for patients with limited alternatives, conducting numerous clinical trials at major medical centers for its investigational compounds. Celgene's research primarily targets incurable hematological cancers, such as multiple myeloma, chronic lymphocytic leukemia, and non-Hodgkin’s lymphoma, as well as solid tumors like pancreatic cancer and melanoma. Additionally, the company is developing therapies for serious inflammatory conditions, including psoriasis and psoriatic arthritis. With a commitment to improving patient outcomes, Celgene continues to advance its pipeline of biopharmaceutical drugs.

Vedanta Biosciences, Inc. is a clinical-stage microbiome company based in Cambridge, Massachusetts, focused on developing therapies for immune-mediated and infectious diseases using human microbiome-derived bacteria. Established in 2010, the company utilizes microbial ecology and mucosal immunology to create innovative immunotherapies. Its platform includes a comprehensive library of bacteria sourced from the human microbiome, proprietary assays for selecting effective bacterial strains, and extensive datasets from human interventional studies. Vedanta also possesses cGMP-compliant manufacturing capabilities, allowing for the production of defined bacterial consortia in powder form. This enables the development of oral therapies aimed at treating autoimmune and inflammatory diseases, providing physicians with effective access to live bacterial drugs. Vedanta operates as a subsidiary of Pure Tech Health plc.

Galecto is a clinical-stage biotechnology company focused on developing small-molecule therapeutics to address severe diseases, particularly fibrosis and cancer. Established in 2011, Galecto builds on over a decade of research into the roles of galectin-3 and lysyl oxidase-like 2 (LOXL2) in fibrotic diseases. The company's lead product candidate, GB0139, is an inhaled galectin-3 inhibitor specifically designed for treating severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis (IPF), where there is a significant unmet medical need. Additionally, Galecto is advancing GB1211, an oral selective galectin-3 inhibitor aimed at addressing fibrosis related to non-alcoholic steatohepatitis. With a robust patent portfolio, Galecto leverages its unique therapeutic platform to target the underlying biological processes associated with fibrosis and related diseases.

Compugen Ltd. is a clinical-stage therapeutic discovery and development company headquartered in Holon, Israel. It specializes in the research, development, and commercialization of novel therapeutic candidates primarily in the field of cancer immunotherapy. The company's immuno-oncology pipeline includes several clinical-stage programs, such as COM701, an anti-PVRIG antibody, and COM902, which targets TIGIT, both designed for the treatment of solid tumors. Compugen employs advanced computational methods for drug discovery, utilizing in silico techniques to predict and select promising drug targets, followed by rigorous experimental validation. The company collaborates with major pharmaceutical partners, including Bayer Pharma AG and Bristol-Myers Squibb, to enhance its research and development efforts. Compugen's focus on innovative therapeutic solutions aims to address significant unmet medical needs in oncology, leveraging its unique predictive capabilities and a robust pipeline of early-stage programs targeting immune resistance mechanisms.

Personal Genome Diagnostics, Inc. specializes in patient-specific cancer genome analysis using advanced digital characterization and monitoring technologies. Founded in 2010 and based in Baltimore, Maryland, the company offers a range of products and services aimed at improving cancer diagnosis and treatment. Their METDetect Assay detects MET gene amplifications in cancer patients' circulation, providing detailed reports on tumor-specific alterations. The LungSelect product identifies actionable genetic changes in plasma from non-small cell lung cancer patients, while PGDx elio plasma resolve is a diagnostic test that detects various genetic alterations in circulating cell-free DNA. Additionally, the company offers RNAcomplete, which allows for the extraction of total RNA and genomic DNA from single tissue samples, and CancerXOME, which analyzes the coding regions of numerous genes. Personal Genome Diagnostics collaborates with institutions like Mayo Clinic and has partnerships with KingMed Diagnostics to further enhance cancer genome research and diagnostics.

Enterome SA is a biopharmaceutical company based in Paris, France, with an additional office in Cambridge, Massachusetts. Founded in 2008, the company specializes in developing innovative disease management solutions that leverage the understanding of the gut microbiome. Enterome focuses on creating biomarkers, companion diagnostics, and therapeutics targeted at microbiome-related diseases, including inflammatory bowel diseases and metabolic disorders. The company’s OncoMimic technology addresses cancer by mimicking tumor-associated antigens, thereby inducing a strong immune response against solid tumors. Enterome's drug candidates are designed to modulate the immune system and are currently advancing through clinical trials, with several programs in Phase 2 targeting challenging cancers such as glioblastoma, adrenal malignancies, and colorectal cancer. The company has formed a strategic collaboration with Takeda Pharmaceutical Company to enhance its research and development efforts.

Akamis Bio is a clinical-stage oncology company dedicated to advancing cancer treatment through its innovative Tumor-Specific Immuno-Gene Therapy (T-SIGn®) platform. The company develops a portfolio of therapeutics specifically targeting solid tumors, aiming to enhance patients' immune responses to recognize and eradicate cancer cells. By harnessing a proprietary intravenously administered viral platform, Akamis Bio focuses on delivering effective gene therapies that address the needs of cancer patients, striving to improve their quality of life and treatment outcomes.

The UNC Center for Aging and Health, part of the University of North Carolina School of Medicine, is dedicated to enhancing the health and wellbeing of older adults in North Carolina and beyond. The center provides high-quality clinical care specifically tailored for older patients and connects families and caregivers with essential community resources. In addition to delivering direct patient care, it focuses on the education and training of the next generation of geriatricians and other healthcare providers, including dentists, pharmacists, cardiologists, and oncologists. The center emphasizes best practices in geriatric medicine that are research-based, patient-centered, and compassionate, ensuring a comprehensive approach to improving care for older adults. Through its mission, the center fosters a diverse and respectful environment that supports the professional development of faculty, staff, and learners.

Enterome SA is a biopharmaceutical company based in Paris, France, with an additional office in Cambridge, Massachusetts. Founded in 2008, the company specializes in developing innovative disease management solutions that leverage the understanding of the gut microbiome. Enterome focuses on creating biomarkers, companion diagnostics, and therapeutics targeted at microbiome-related diseases, including inflammatory bowel diseases and metabolic disorders. The company’s OncoMimic technology addresses cancer by mimicking tumor-associated antigens, thereby inducing a strong immune response against solid tumors. Enterome's drug candidates are designed to modulate the immune system and are currently advancing through clinical trials, with several programs in Phase 2 targeting challenging cancers such as glioblastoma, adrenal malignancies, and colorectal cancer. The company has formed a strategic collaboration with Takeda Pharmaceutical Company to enhance its research and development efforts.

Cardioxyl Pharmaceuticals is a privately held, clinical stage biopharmaceutical company focused on developing therapies for cardiovascular disease. The company specializes in nitroxyl technology, which is aimed at addressing areas of cardiovascular treatment where existing therapies are lacking or ineffective. Cardioxyl has developed a robust portfolio of pre-clinical and clinical candidates, with its lead compound, CXL-1020, currently in clinical development for Acute Decompensated Heart Failure, a prevalent condition among patients over 65 years of age that often leads to hospitalization. Through its innovative approach, Cardioxyl aims to enhance treatment options for patients suffering from cardiovascular diseases.

Flexus Biosciences is a privately-held biopharmaceutical company established in 2013 and headquartered in San Carlos, California. The company specializes in the creation, development, and commercialization of innovative anti-cancer therapeutics, particularly through the application of insights in immunology. Flexus focuses on developing small-molecule cancer therapeutics that specifically target regulatory T cells. This targeted approach aims to enhance the effectiveness of cancer treatments, enabling healthcare providers to better address the complexities of cancer care.

CareDx, Inc. is a precision medicine company that specializes in developing and commercializing innovative healthcare solutions for transplant patients and their caregivers. The company offers a range of molecular diagnostics products, including AlloSure Kidney and AlloMap Heart, which utilize donor-derived cell-free DNA to assess organ transplant health and identify potential rejections noninvasively. CareDx also provides various solutions for human leukocyte antigen typing, chimerism testing, and post-transplant monitoring. Its offerings extend to patient tracking software and predictive analysis tools, enhancing the overall transplant experience from initial matching to ongoing care. Founded in 1998 and headquartered in South San Francisco, California, CareDx has established partnerships for the development and distribution of advanced genomic testing technologies, further solidifying its role as a leader in transplant diagnostics.

Medarex is a biopharmaceutical company dedicated to the discovery and development of fully human antibody-based therapeutics aimed at addressing life-threatening and debilitating diseases, including cancer, autoimmune disorders, inflammation, and infectious diseases. The company utilizes its proprietary UltiMAb technology along with its expertise in product development and clinical manufacturing to create a diverse range of human antibody product candidates. Medarex seeks not only to advance its own therapeutics but also to collaborate with partners for potential commercialization, focusing on improving patient outcomes through innovative treatments.

ImClone Systems is a leader in the development and manufacture of therapeutic antibodies, focused on advancing oncology care through targeted biologic treatments for various cancers. Established in 1984, the company has cultivated a strong expertise in oncology and utilizes advancements in molecular biology, genomics, and antibody engineering to create a unique pipeline of product candidates aimed at specific genetic mechanisms involved in cancer progression. Besides its marketed product ERBITUX, ImClone is advancing several investigational monoclonal antibodies through various stages of clinical development, targeting major solid tumor types. Following its acquisition by Eli Lilly and Company in 2008, the company has enhanced its antibody pipeline by leveraging Lilly's global resources. ImClone's capabilities are further strengthened by its state-of-the-art, FDA-approved manufacturing facilities in Branchburg, New Jersey, which provide significant capacity for biologic production. The company's research headquarters are located in New York City, and it maintains international operations in Europe, emphasizing its commitment to addressing the medical needs of cancer patients worldwide.

Kosan Biosciences Incorporated, a cancer therapeutics company, focuses on developing various classes of anticancer agents through clinical development. Its product KOS-953, a Hsp90 inhibitor is in Phase III clinical trial in combination with Velcade for multiple myeloma, as well as in Phase II clinical trial in combination with Herceptin for HER2-positive metastatic breast cancer. The company's product portfolio also includes KOS-1584, an epothilone anticancer product candidate evaluated in dose-escalating Phase I clinical trial in patients with solid tumors; KOS-1803, a preclinical stage product for cancer; KOS-2187, a potent motilin receptor agonist that is in Phase I clinical testing for the treatment of GERD. In addition, Kosan Biosciences develops KOS-2464, a preclinical stage product for cancer. The company was founded in 1995 and is based in Hayward, California. As of June 25, 2008, Kosan Biosciences Incorporated operates as a subsidiary of Bristol-Myers Squibb Co.

Adnexus, a Bristol-Myers Squibb R&D Company, specializes in the discovery and development of Adnectins, a unique class of targeted biologics. These proteins are engineered to block or stimulate therapeutic targets to combat various diseases, addressing significant medical needs in oncology, immunology, and cardiovascular health. Utilizing a proprietary protein engineering system known as PROfusion™, Adnexus can generate a vast library of over 10 trillion potential Adnectins. This technology enhances the efficiency of identifying candidates with desirable therapeutic properties. Among its product candidates is Angiocept/CT-322, an anti-angiogenesis agent aimed at treating cancer by inhibiting the VEGFR-2 pathway. Since its acquisition by Bristol-Myers Squibb in 2007, Adnexus has further advanced its capabilities in developing innovative medicines to improve patient outcomes.

GlycoEra is a biotechnology research company focused on developing innovative therapeutics to address significant unmet medical needs in areas such as inflammatory diseases, autoimmune disorders, and immune-oncology. The company utilizes a proprietary platform to create first-in-class biologics that feature customized and highly homogeneous human glycans assembled onto glycoproteins in a site-specific manner. This approach enables healthcare companies to gain insights into the role of glycans in human health and disease, ultimately advancing the development of novel treatments.